Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Stopped early · Phase 1

Conditions studied: Neoplasm Metastasis

In brief

A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors

Key facts

Study ID

NCT04458259

Run by

Pfizer

People needed

88

Starts

2020-09-24

Expected to finish

2024-11-15

Last updated by the study team

2026-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least one measurable (Parts 1-4) or non-measurable lesion (Parts 1-3), not previously irradiated, as defined by RECIST 1.1
• ECOG Performance Status 0 or 1, 2 with approval
• Adequate Bone Marrow Function
• Adequate Renal Function
• Adequate Liver Function
• Resolved acute effects of any prior therapy
• Able to provide adequate archival tumor tissue or freshly obtained tumor tissue (some participants will require mandatory pre- and on-treatment biopsy is part of the biomarker cohort).
• Life expectancy of at least 3 months.
• Part 1 and Part 2: Participants who are intolerant or resistant to standard treatment for selected solid tumors.
• Part 3: Participants with advanced/metastatic RCC with a clear cell component and progressed with no standard therapy available.
• Part 4, Cohort 1: Participants with NSCLC with METex14-skipping alteration(s) and progressed on at least 1 prior therapy.
• Part 4, Cohort 2: Participants with MSS CRC with intermediate TMB and progressed with no satisfactory alternative treatment available, but has not received prior treatment with an anti-PD-(L)1 therapy.
• Part 4, Cohort 3: Participants with metastatic gastric or GEJ adenocarcinoma that is PD-L1 positive that has progressed on at least 2 but no more than 3 prior chemotherapy regiments, but has not received prior treatment with an anti-PD-(L)1 therapy.
• Part 4, Cohort 4: Participants with metastatic RCC with a clear cell component with IMDC intermediate or poor risk that have not received any prior systemic therapy for metastatic disease.

You may not qualify if…

• Known active uncontrolled or symptomatic CNS metastases.
• Any other active malignancy within 2 years prior to enrollment.
• Major surgery within 6 weeks, radiation therapy within 4 weeks, systemic anti-cancer therapy within 2 week or 5 half-lives (4 weeks or 5 half-lives for antibody therapies or investigational drug(s) taken on another study) prior to study entry.
• Active or history of autoimmune disease requiring >10mg/day prednisone or other concurrent immunosuppressive therapy.
• Active, uncontrolled infection (controlled HBV, HCV, HIV/AIDS may be allowed) as defined in protocol.
• Retinal or other serious ophthalmic disorders as defined in protocol.
• Clinically significant cardiac disease as defined in protocol.
• Uncontrolled HTN that cannot be controlled by medications.
• Inability to consume or absorb study drug.
• Known or suspected hypersensitivity to PF-07265807.
• Prohibited concomitant medications as defined in protocol.
• Active inflammatory GI disease, uncontrollable chronic diarrhea, or previous gastric resection or lap band surgery affecting absorption.
• Active bleeding disorder.
• Discontinuation of prior checkpoint inhibitor for treatment-related toxicity.
• Experienced >= G3 treatment-related irAE with prior PD-(L)1 agent.
• Prior treatment with selective AXL/MERTK inhibitors
• For participants receiving sasanlimab:
• Known history of non-infectious pneumonitis that required steroid treatment or current pneumonitis.

Where it is running

• Henry Eye Clinic — Fayetteville, Arkansas, United States
• Highlands Oncology Group — Fayetteville, Arkansas, United States
• Highlands Oncology Group — Rogers, Arkansas, United States
• Highlands Oncology Group — Springdale, Arkansas, United States
• UCI Chao Family Comprehensive Cancer Center — Orange, California, United States
• Clinical & Translational Science Institute — San Francisco, California, United States
• UCSF Helen Diller Family Comprehensive Cancer Center - Mission Hall — San Francisco, California, United States
• UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States
• Rocky Mountain Lions Eye Institute (RMLEI) — Aurora, Colorado, United States
• University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) — Aurora, Colorado, United States
• University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) — Aurora, Colorado, United States
• University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) — Aurora, Colorado, United States
• Community Health Network, Inc. — Indianapolis, Indiana, United States
• Community Health Network, Inc. — Indianapolis, Indiana, United States
• Community Health Network Cancer Center North — Indianapolis, Indiana, United States
• Community Health Network, Inc. — Indianapolis, Indiana, United States
• Community Health Network, Inc. — Indianapolis, Indiana, United States
• Brigham & Women's Hospital — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute - Chestnut Hill — Newton, Massachusetts, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States
• Duke Eye Center — Durham, North Carolina, United States
• Duke University Medical Center, lnvestigational Chemotherapy Service — Durham, North Carolina, United States
• The University of Texas M. D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.